Our Leadership Team
Cancer52 benefits hugely from the expertise and skills of those individuals who give their time to help drive forward the agenda for rare and less common cancers. All are strong, senior and experienced individuals at board and strategy level, established and credible in their own right.
The board of directors was initially established in early 2012 alongside the creation of the organisation’s status as a not for profit company limited by guarantee. Board membership has been updated since and continues to represent a vibrant and experienced group of people committed to the aims of Cancer52.
Baroness Morgan of Drefelin (Chief Executive of Breast Cancer Now) sits at the helm of the organisation as honorary president, giving Cancer52 both a route
through to the seat of government, as well as guidance on the lessons to be learnt from the bigger cancer organisations.
The board is responsible for shaping the direction of Cancer52, supporting its Chair Anne MacDowell.
Honorary President Cancer52
Baroness Delyth
Morgan
Chair, Cancer52
Anne MacDowell
CEO, Cancer52
Jane
Lyons
CEO, AMMF The Cholangiocarcinoma Charity
Helen Morement
CEO, The Urology Foundation
Rebecca Porta
Head of Policy & Campaigns, Blood Cancer UK
Chris Walden
Doctor
Dr Max Brodermann
Retired Financial Consultant
Michael Draeger
Research Assistant
Sophie Davies
